Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine

Vaccine

Volumn 30, Issue 31, 2012, Pages 4638-4643

  Partidos, Charalambos D ^a   Paykel, Joanna ^a   Weger, James ^b   Borland, Erin M ^c   Powers, Ann M ^c   Seymour, Robert ^d   Weaver, Scott C ^d   Stinchcomb, Dan T ^e   Osorio, Jorge E ^a,b  

^a Inviragen Inc   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^d University of Texas Medical Branch School of Medicine   (United States)

^e Inviragen Inc   (United States)

Author keywords

A129 mice; Chikungunya virus (CHIKV); Interferon (IFN); Maternal fetal immunity; O'nyong nyong virus (ONNV)

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; ANTISERUM; CHIKUNGUNYA VACCINE; GAMMA INTERFERON RECEPTOR; NEUTRALIZING ANTIBODY; RECOMBINANT VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; CROSS PROTECTION; DISEASE MODEL; DRUG RESPONSE; FEMALE; MALE; MOUSE; NONHUMAN; O NYONG NYONG ALPHAVIRUS; O NYONG NYONG VIRUS INFECTION; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROGENY; SINGLE DRUG DOSE; TOGAVIRUS; TOGAVIRUS INFECTION;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHIKUNGUNYA VIRUS; CROSS PROTECTION; FEMALE; IMMUNIZATION, PASSIVE; MALE; MICE; NEUTRALIZATION TESTS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL PLAQUE ASSAY; VIRAL VACCINES;

EID: 84861977697     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.099     Document Type: Article

References (29)

1. Haddow A.J., Davies C.W., Walter A.J. O'nyong-nyong fever: an epidemic virus disease in East Africa-introduction. Transactions of the Royal Society of Tropical Medicine and Hygiene 1960, 54:517-522.
2. Lanciotti R.S., Ludwig M.L., Rwaguma E.B., Lutwama J.J., Kram T.M., Karabatsos N., et al. Emergence of epidemic o'nyong-nyong fever in Uganda after a 35-year absence: genetic characterization of the virus. Virology 1998, 252:258-268.
3. Powers A.M., Logue C.H. Changing patterns of chikungunya virus: re-emergence of a zoonotic arbovirus. Journal of General Virology 2007, 88:2363-2377.
4. Powers A.M., Brault A.C., Tesh R.B., Weaver S.C. Re-emergence of chikungunya and o'nyong-nyong viruses: evidence for distinct geographical lineages and distant evolutionary relationships. Journal of General Virology 2000, 81:471-479.
5. Grandadam M., Caro V., Plumet S., Thiberge J.M., Souarès Y., Failloux A.B., et al. Chikungunya virus, southeastern France. Emerging Infectious Diseases 2011, 17:910-913.
6. Poletti P., Messeri G., Ajelli M., Vallorani R., Rizzo C., Merler S. Transmission potential of chikungunya virus and control measures: the case of Italy. PLoS One 2011, 6:e18860.
7. Karabatsos N. Antigenic relationships of group A arboviruses by plaque reduction neutralization testing. The American Journal of Tropical Medicine and Hygiene 1975, 24:527-532.
8. Chanas A.C., Hubalek Z., Johnson B.K., Simpson D.I. A comparative study of O'nyong nyong virus with chikungunya virus and plaque variants. Archives of Virology 1979, 59:231-238.
9. Blackburn N.K., Besselaar T.G., Gibson G. Antigenic relationship between chikungunya virus strains and o'nyong nyong virus using monoclonal antibodies. Research in Virology 1995, 146:69-73.
10. Wang E., Volkova E., Adams A.P., Forrester N., Xiao S.Y., Frolov I., et al. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 2008, 26:5030-5039.
11. Levitt N.H., Ramsburg H.H., Hasty S.E., Repik P.M., Cole F.E, Lupton H.W. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 1986, 3:157-162.
12. Harrison V.R., Eckels K.H., Bartelloni P.J., Hampton C. Production and evaluation of a formalin-killed chikungunya vaccine. Journal of Immunology 1971, 107:643-647.
13. Tiwari M., Parida M., Santhosh S.R., Khan M., Dash P.K., Rao P.V. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of chikungunya virus. Vaccine 2009, 27:2513-2522.
14. Muthumani K., Lankaraman K.M., Laddy D.J., Sundaram S.G., Chung C.W., Sako E., et al. Immunogenicity of novel consensus-based DNA vaccines against chikungunya virus. Vaccine 2008, 26:5128-5134.
15. Akahata W., Yang Z.-Y., Andersen H., Sun S., Holdaway H.A., Kong W.-P., et al. A virus-like particle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nature Medicine 2010, 16:334-338.
16. Wang D., Suhrbier A., Penn-Nicholson A., Woraratanadharm J., Gardner J., Luo M., et al. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 2011, 29:2803-2809.
17. Volkova E., Frolova E., Darwin J., Forrester N.L., Weaver S.C., Frolov I. IRES-dependent replication of Venezuelan equine encephalitis virus makes it highly attenuated and incapable of replicating in mosquito cells. Virology 2008, 377:160-169.
18. Plante K., Wang E., Partidos C.D., Weger J., Gorchakov R., Tsetsarkin K., et al. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathogens 2011, 7:e1002142.
19. Couderc T., Chrétien F., Schilte C., Disson O., Brigitte M., Guivel-Benhassine F., et al. A mouse model for chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathogens 2008, 4:e29.
20. Griffin D., Levine B., Tyor W., Ubol S., Desprès P. The role of antibody in recovery from alphavirus encephalitis. Immunological Reviews 1997, 159:151-159.
21. Couderc T., Khandoudi N., Grandadam M., Visse C., Gangneux N., Bagot S., et al. Prophylaxis and therapy for chikungunya virus infection. Journal of Infectious Diseases 2009, 200:516-523.
22. Partidos C.D., Weger J., Brewoo J., Seymour R., Borland E.M., Ledermann J.P., et al. Probing the attenuation and protective efficacy of a candidate chikungunya virus vaccine in mice with compromised interferon (IFN) signaling. Vaccine 2011, 29:3067-3073.
23. Khan A.H., Morita K., Parquet Md Mdel C., Hasebe F., Mathenge E.G., Igarashi A. Complete nucleotide sequence of chikungunya virus and evidence for an internal polyadenylation site. Journal of General Virology 2002, 83:3075-3084.
24. Levinson R.S., Strauss J.H., Strauss E.G. Complete sequence of the genomic RNA of o'nyong-nyong virus and its use in the construction of alphavirus phylogenetic trees. Virology 1990, 175:110-123.
25. Kam Y.W., Lum F.M., Teo T.H., Lee W.W., Simarmata D., Harjanto S., et al. Early neutralizing IgG responses to chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Molecular Medicine 2012, 4:1-14.
26. Warter L., Lee C.Y., Thiagarajan R., Grandadam M., Lebecque S., Lin R.T., et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. Journal of Immunology 2011, 186:3258-3264.
27. Lee C.Y., Kam Y.W., Fric J., Malleret B., Koh E.G., Prakash C., et al. Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants. PLoS Pathogens 2011, 7:e1002390.
28. Levy O. Innate immunity of the newborn: basic mechanisms and clinical correlates. Nature Reviews Immunology 2007, 7:379-390.
29. Byrnes A.P., Durbin J.E., Griffin D.E. Control of Sindbis virus infection by antibody in interferon-deficient mice. Journal of Virology 2000, 74:3905-3908.